Skip to main content
    A

    AN2 Therapeutics Inc (ANTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.47
    -0.08 (-1.76%)

    Market Cap: $172.64M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    AN2 Therapeutics Inc (ANTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    AN2 Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$35.17M, operating cash flow was -$29.83M and free cash flow was -$29.83M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$7.96M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $38.11M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Research and development$24.77M$40.49M$54.87M$29.51M$16.91M$6.02M$29.33M
    Operating income-$38.11M-$56.79M-$69.64M-$42.26M-$21.57M-$7.28M-$31.07M
    Net income-$35.17M-$51.32M-$64.73M-$40.96M-$21.54M-$13.60M-$33.81M
    EBITDAN/AN/AN/AN/A-$21.56M-$7.28M-$5.18M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$0$0$0$0$80.00K
    Gross profit$0$0$0N/A$0$0$0N/A$0$0$0$40.00K
    Operating income-$8.67M-$8.90M-$10.55M-$9.32M-$10.04M-$7.22M-$11.54M-$8.60M-$14.01M-$15.88M-$18.30M-$18.82M
    Net income-$7.96M-$8.19M-$10.03M-$8.71M-$9.35M-$6.46M-$10.65M-$7.52M-$12.75M-$14.44M-$16.62M-$16.90M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $19.94M were 32.2% of total assets of $61.95M, against total liabilities of $8.89M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$61.95M$92.09M$138.74M$102.56M$65.32M$4.23M$5.70M
    Current assets$59.94M$86.26M$110.51M$98.62M$60.11M$4.23M$5.70M
    Cash and equivalents$19.94M$21.35M$15.65M$27.22M$12.10M$4.07M$5.60M
    Total liabilities$8.89M$10.24M$14.04M$7.19M$3.41M$1.48M$887.00K
    Short-term debtN/AN/AN/A$53.00KN/AN/AN/A
    Shareholder equity$53.06M$81.85M$124.70M$95.37M-$47.41M$2.75M$4.81M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$81.95M$81.68M$87.49M$61.95M$67.23M$75.83M$81.34M$92.09M$97.69M$108.48M$121.26M$138.74M
    Total liabilities$6.45M$5.75M$5.73M$8.89M$6.86M$6.98M$8.01M$10.24M$10.02M$10.13M$10.66M$14.04M
    Cash and equivalents$20.21M$44.32M$53.49M$19.94M$18.00M$18.22M$19.98M$21.35M$33.50M$26.77M$24.69M$15.65M
    Shareholder equity$75.51M$75.92M$81.76M$53.06M$60.38M$68.84M$73.33M$81.85M$87.67M$98.35M$110.60M$124.70M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$29.83M-$49.26M-$53.29M-$33.46M-$20.48M-$5.36M-$2.49M
    Free cash flow-$29.83M-$49.26M-$53.29M-$33.46M-$20.48M-$5.36M-$2.49M
    Dividends paidN/AN/AN/A$1.82MN/AN/AN/A
    Share repurchasesN/AN/AN/AN/A$1.21MN/AN/A
    Investing cash flow$28.31M$54.59M-$43.28M-$21.77M-$50.02M-$50.02M-$50.02M
    Financing cash flow$113.00K$372.00K$84.99M$70.36M$78.53M$3.84M$8.08M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.10M-$7.00M-$12.07M-$5.24M-$6.38M-$7.60M-$10.62M-$5.27M-$12.01M-$14.38M-$17.59M-$17.07M
    Free cash flowN/AN/A-$12.07M-$5.24M-$6.38M-$7.60M-$10.62M-$5.27M-$12.01M-$14.38M-$17.59M-$17.07M
    Last 12 quarters

    Frequently Asked Questions About ANTX

    What is AN2 Therapeutics' annual revenue?

    AN2 Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is AN2 Therapeutics profitable?

    No. AN2 Therapeutics reported net income of -$35.17M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ANTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$29.83M minus capital expenditures of $0 produced free cash flow of -$29.83M.

    How much debt does AN2 Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $19.94M.